| Trial ID: | L2632 |
| Source ID: | NCT01507389
|
| Associated Drug: |
Liraglutide
|
| Title: |
Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide
|
| Outcome Measures: |
Primary: Area under the Curve (0-infinity) | Secondary: Area under the Curve (0-t)|Cmax, maximum concentration|tmax, time to maximum concentration|t½, terminal half-life|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-03
|
| Completion Date: |
2006-06
|
| Results First Posted: |
|
| Last Update Posted: |
2014-12-09
|
| Locations: |
Warszawa, 01-201, Poland
|
| URL: |
https://clinicaltrials.gov/show/NCT01507389
|
